Current Report Filing (8-k)
February 16 2022 - 7:40AM
Edgar (US Regulatory)
0001644963
false
0001644963
2022-02-15
2022-02-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
February 15, 2022
Avenue Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction
of Incorporation) |
001-38114
(Commission File Number)
|
47-4113275
(IRS Employer Identification No.)
|
1140 Avenue of the Americas, Floor 9
New York, New York 10036
(Address of Principal Executive Offices)
(781) 652-4500
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act. |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
¨ |
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Securities registered pursuant to Section 12(b) of the Exchange
Act:
Title of Class |
Trading Symbol(s) |
Exchange Name |
Common Stock |
ATXI |
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
On February 15, 2022, Avenue
Therapeutics, Inc., announced the outcome of the U.S. Food and Drug Administration joint meeting of the Anesthetic and Analgesic Drug
Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on the Company’s New Drug Application for
IV Tramadol. A copy of such press release is being furnished as Exhibit 99.1 to this report.
Item 9.01. |
Financial Statements and Exhibits. |
The following exhibit is furnished herewith:
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
AVENUE THERAPEUTICS, INC. |
|
(Registrant) |
Date: February 16, 2022 |
|
|
By: |
/s/ Lucy Lu, M.D. |
|
Name: |
Lucy Lu, M.D. |
|
Title: |
President and Chief Executive Officer |
Avenue Therapeutics (NASDAQ:ATXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avenue Therapeutics (NASDAQ:ATXI)
Historical Stock Chart
From Apr 2023 to Apr 2024